Patent ID: 9198955
Filing Date: 2015-12-01
Classification: A61K,A61P,C07K

Abstract:
1. A method for reducing the severity of flu-like symptoms associated with treating a patient having multiple sclerosis with intramuscularly administered interferon-β-1a over an eight week period, comprising once a week intramuscular administration of interferon-β-1a to a patient having multiple sclerosis according to a first schedule comprising intramuscular administration of 7.5 micrograms of interferon-β1a to the patient in week one, intramuscular administration of 15 micrograms of interferon-β-1a to the patient in week two, intramuscular administration of 22.5 micrograms of interferon-β-1a to the patient in week 3, and intramuscular administration of 30 micrograms of interferon-β-1a to the patient in week 4 and each week thereafter, wherein the severity of flu-like symptoms is reduced at 4 6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a to the patient throughout the eight week period when compared to the severity of flu-like symptoms at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a to a patient having multiple sclerosis according to (i) a second schedule comprising once a week intramuscular administration of 30 micrograms of interferon-β-1a to the patient having multiple sclerosis for eight weeks and (ii) a third schedule comprising intramuscular administration of 7.5 micrograms of interferon-β-1a to the patient in weeks one and two, intramuscular administration of 15 micrograms of interferon-β-1a to the patient in weeks three and four, intramuscular administration of 22.5 micrograms of interferon-β-1a to the patient in weeks five and six and intramuscular administration of 30 micrograms of interferon-β-1a to the patient in week seven and each week thereafter.